SSS Sunvest Minerals Corp

Stem Cell Therapeutics Corp. (TSX VENTURE:SSS)(OTCQX:SCTPF), an immuno-oncology
company developing cancer stem cell-related therapeutics, is pleased to announce
that its Board of Directors has elected Dr. Calvin R. Stiller as Chairman of the
Board. Dr. Stiller has been a member of the Board since July 2011 and served as
Lead Director and Chair of the Governance and Nominating Committee. 


Dr. Stiller is well known in the biotechnology community having served in
various capacities in the public and private sector. He was the founding Chair
of Trillium Therapeutics, which recently merged with Stem Cell Therapeutics, as
well as Verio Therapeutics, which was acquired by FATE Therapeutics
(NASDAQ:FATE). He was also the founding chair of Oracle Services Network, which
he grew from 50 employees to over 800 at the time of its acquisition by SYKES
Corporation (NASDAQ:SYKE). Dr. Stiller also served on the Board of Allelix
Biopharmaceuticals and was instrumental in its very successful merger with NPS
Pharmaceuticals (NASDAQ:NPSP), where he remained a director for several years.
He currently serves on the board of Revera, one of Canada's largest HealthCare
companies, where he chairs the Investment Committee. Dr. Stiller is recognized
as co-founder of the Ontario Institute for Cancer Research (of which he is
Chair), MaRS Discovery District (of which he is a director), and the
Canadian-California Cancer Stem Cell Initiative. He is an Officer of the Order
of Canada, a member of the Order of Ontario, and a laureate of the Canadian
Medical Hall of Fame. 


"I am pleased to be asked to chair the Board of this most exciting company that,
in the past nine months, has emerged from the shadows to become a potential
leader in the area of immunotherapy targeting cancer stem cells. The science
behind the assets of this company is truly spectacular and the quality of the
people responsible for the science, including Dr. John Dick, who has been
credited with the discovery of the leukemic cancer stem cell and who serves on
the company's Scientific Advisory Board, are without peers. Management's ability
to raise the unprecedented amount of 33 million from some of the smartest
investors on the continent, largely on the back of a preclinical asset, is quite
remarkable. So, to be asked to Chair a company with first-class scientific
assets, a talented management team, a principled and knowledgeable board, and
backed by some of the shrewdest investors, is a real honor."


Dr. Niclas Stiernholm, the company's President and CEO, commented "Management is
very pleased that Dr. Stiller has assumed the Chairmanship. We worked well
together in a highly successful relationship at Trillium, and more recently
during our time here at Stem Cell Therapeutics, under his oversight as a member
of the Board and Lead Director. We look forward to a seamless path forward for
the company."


The company also announces that the Board of Directors has granted options to
purchase 200,000 common shares of the Corporation to a newly appointed director.
The options were issued at an exercise price of $0.51 per share for a ten-year
term. The grant of options is subject to acceptance by the TSX Venture Exchange.


About Stem Cell Therapeutics: 

Stem Cell Therapeutics Corp. (SCT) is an immuno-oncology company advancing
cancer stem cell discoveries into novel and innovative cancer therapies.
Building on over half a century of leading and groundbreaking Canadian stem cell
research, the company is supported by established links to a group of prominent
Toronto academic research institutes and cancer treatment centers, representing
one of the world's most acclaimed cancer research hubs. The Company has two
premier preclinical programs, SIRPaFc and a CD200 monoclonal antibody (mAb),
which target two key immunoregulatory pathways that tumor cells exploit to evade
the host immune system. SIRPaFc is an antibody-like fusion protein that blocks
the activity of CD47, a molecule that is upregulated on cancer stem cells in AML
and several other tumors. The CD200 mAb is a fully human monoclonal antibody
that blocks the activity of CD200, an immunosuppressive molecule that is
overexpressed by many hematopoietic and solid tumors. SCT's clinical stage
programs include the recently in-licensed program focused on the structure of
tigecycline, which is currently being evaluated in a multi-centre Phase I study
in patients with acute myeloid leukemia (AML), as well as TTI-1612, a non-cancer
stem cell asset that recently completed a 28-patient Phase I trial in
interstitial cystitis ("IC") patients. For more information, visit:
www.stemcellthera.com 


Caution Regarding Forward-Looking Information: 

This press release may contain forward-looking statements, which reflect SCT's
current expectation regarding future events. These forward-looking statements
involve risks and uncertainties that may cause actual results, events or
developments to be materially different from any future results, events or
developments expressed or implied by such forward-looking statements. Such
factors include changing market conditions; the successful and timely completion
of pre-clinical and clinical studies; the establishment of corporate alliances;
the impact of competitive products and pricing; new product development risks;
uncertainties related to the regulatory approval process or the ability to
obtain drug product in sufficient quantity or at standards acceptable to health
regulatory authorities to complete clinical trials or to meet commercial demand;
and other risks detailed from time to time in SCT's ongoing quarterly and annual
reporting. Except as required by applicable securities laws, SCT undertakes no
obligation to publicly update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Stem Cell Therapeutics Corp.
James Parsons
Chief Financial Officer
+1 416 595 0627
jparsons@stemcellthera.com
www.stemcellthera.com


Investor Contact:
ProActive Capital
Jeff Ramson/Kirin Smith
+1 646-863-6519
jramson@proactivecapital.com / ksmith@proactivecapital.com

Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From May 2024 to Jun 2024

Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jun 2023 to Jun 2024